ArticleJournal of the American Heart Association2022
Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- FGF23 - A hormone produced by bone and has many faces.Reviews in endocrine & metabolic disorders · 2026Review
- Vitamin-D and associated biomarker profiles in patients with chronic heart failure.Pakistan journal of medical sciences · 2026Article
- Novel biomarkers distinguish heart failure with preserved vs reduced ejection fraction.ESC heart failure · 2026Observational
- Pre- and post-diagnosis signalling lipid profiles in heart failure with preserved ejection fraction: a prospective cohort study.EBioMedicine · 2026Article
- Endocrine crosstalk in cardiovascular-kidney-metabolic syndrome-related heart failure: the fibroblast growth factor 23-Klotho axis and cardiometabolic therapy.Frontiers in endocrinology · 2026Review
- Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity.Journal of the American College of Cardiology · 2025Review
- Molecular Diagnostics in Heart Failure: From Biomarkers to Personalized Medicine.Diagnostics (Basel, Switzerland) · 2025Review
- Klotho plasma levels are an independent predictorof mortality in women with acute coronary syndrome.Scientific reports · 2025Article
- New Biomarkers in the Prognostic Assessment of Acute Heart Failure with Reduced Ejection Fraction: Beyond Natriuretic Peptides.International journal of molecular sciences · 2025Article
- Fibroblast growth factor 23 independently predicts adverse outcomes after an acute coronary syndrome.ESC heart failure · 2024Article
- FGF23 and klotho at the intersection of kidney and cardiovascular disease.Nature reviews. Cardiology · 2024Review
- Fibroblast Growth Factor 23 and Risk of Heart Failure Subtype: The CRIC (Chronic Renal Insufficiency Cohort) Study.Kidney medicine · 2023Article
- Is there a role in acute kidney injury for FGF23 and Klotho?Clinical kidney journal · 2023Review
- Direct and indirect effects of fibroblast growth factor 23 on the heart.Frontiers in endocrinology · 2023Review
- MCP1 Could Mediate FGF23 and Omega 6/Omega 3 Correlation Inversion in CKD.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The role of fibroblast growth factor 23 (FGF23) in the development of new-onset heart failure (HF) with reduced (HFrEF) or preserved ejection fraction (HFpEF) in the general population is unknown. Therefore, we set out to investigate associations of C-terminal FGF23 with development of new-onset HF and, more specifically, with HFrEF or HFpEF in a large, prospective, population-based cohort. Methods and Results We studied 6830 participants (aged 53.8±12.1 years; 49.7% men; estimated glomerular filtration rate, 93.1±15.7 mL/min per 1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.